Nucleus is a next-generation consumer genetic testing and analysis company building a DTC genetic testing platform that provides innovative genetic risk and disposition score analyses on an extensive number of diseases and traits by leveraging whole-genome sequencing (WGS).

Nucleus' mission is to empower people to take agency over their health so no one dies from preventable disease.

Nucleus was founded in 2021 by Kian Sadeghi. The company is headquartered in New York, NY.


Nucleus provides WGS genetic testing kits for users to receive rare variant analysis and polygenic scores across a wide variety of diseases and traits — ranging from breast cancer risk to longevity disposition.


Nucleus is also bridging the gap between people, doctors, and scientists to help discoveries, therapies, and cures find their way to people faster.


Nucleus is backed by Seven Seven Six, Founders Fund, Quiet Capital, Salt Fund, Bluewatch Ventures, Adrian Aoun (CEO, Forward Health), Brent Saunders (former CEO, Allergan), and others. The company raised $14M in a Seed round on Jul 14, 2022. This brings Nucleus' total funding to $17.5M to date.




  • Year founded: 2021
  • Funding Info: $17.5M over 2 Rounds (Latest Funding Type: Seed- Series Unknown)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: New York
  • State: New York
  • Country: United States
Related businesses